| abstract |
REFERS TO 2,3-DIHYDRO-1H-INDENE COMPOUNDS OF FORMULA (I) WHERE RE, RW, Z1, Z3, X1, X2, X3, X4, t AND w ARE AS DEFINED IN THE DESCRIPTION. THE PREFERRED COMPOUNDS ARE: ACID (R) -1 - ((6 - (((S) -4- (2-CHLORINE-3- (6-METOXY-5 - (((((S) -5-OXOPYRROLIDIN-2 -IL) METHYL) AMINO) METHYL) PYRIDIN-2-IL) PHENYL) -2,3-DIHYDRO-1H-INDEN-1-IL) AMINO) -2-METOXY-5- (TRIFLUOROMETHYL) PYRIDIN-3-IL) METHYL) -3-METHYLPYRROLIDINE-3-CARBOXYL; ACID (R) -1- (5-CHLORO-4 - (((S) -4- (2-CHLORO-3- (6-METOXY-5 - (((((S) -5-OXOPYRROLIDIN-2- IL) METHYL) AMINO) METHYL) PYRIDIN-2-IL) PHENYL) -2,3-DIHYDRO-1H-INDEN-1-IL) AMINO) -2-METOXYBENZYL) -3-METHYLPYRROLIDINE-3-CARBOXYL; AMONG OTHERS. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF PD-1, PD-L1 OR THE INTERACTION PD-1 / PD-L1, BEING USEFUL IN THE TREATMENT OF PANCREATIC CANCER, BLADDER CANCER, COLORECTAL CANCER, BREAST CANCER. |